References
- Lalanza JF, Snoeren EMS. The cafeteria diet: A standardized protocol and its effects on behavior. Neurosci Biobehav Rev. 2021;122:92-119.
- Muscogiuri G, El Ghoch M, Colao A, et al. European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis. Obes Facts. 2021;14(2):222-45.
- El-Arabey AA. Update on off label use of metformin for obesity. Prim Care Diabetes. 2018;12(3):284-5.
- Singh S, Usman K, Banerjee M. Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes. 2016;7(15):302-15.
- Committee ADAPP. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes – 2022. Diabetes Care. 2021; 45(Suppl_1):S113-S24.
- Hansen KB, Vilsboll T, Knop FK. Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes a review. Diabetes Metab Syndr Obes. 2010; 3:155-63.
- Campbell Jonathan E, Drucker Daniel J. Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism. 2013; 17(6):819-37.
- Jakhar K, Vaishnavi S, Kaur P, et al. Pharmacogenomics of GLP-1 receptor agonists: Focus on pharmacological profile. Eur J Pharmacol. 2022; 936:175356.
- Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study. Neurogastroenterol Motil. 2018; 30(7):e13313.
- Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011; 2011:279530.
- Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017; 10:223-34.
- Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013; 121(1):27-31.
- Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5):1422-31.
- Hyrsova L, Smutny T, Trejtnar F, Pavek P. Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation. Drug Metab Rev. 2016; 48(2):139-58.
- Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017; 60(9):1648-55.
- Becker ML, Visser LE, van Schaik RH, et al. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010; 20(1):38-44.
- Todd JN, Florez JC. An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics. 2014; 15(4):529-39.
- Zolk O. Disposition of metformin: Variability due to polymorphisms of organic cation transporters. Annals of Medicine. 2012; 44(2):119-29.
- Toyama K, Yonezawa A, Masuda S, et al. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformininduced lactic acidosis. Br J Pharmacol. 2012; 166(3):1183-91.
- Okuda M, Saito H, Urakami Y, et al. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun. 1996; 224(2):500-7.
- Chan SL, Samaranayake N, Ross CJ, et al. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics. 2016; 26(1):28-39.
- Belzung C, Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol Mood Anxiety Disord. 2011; 1(1):9.
- Caimari A, Oliver P, Keijer J, Palou A. Peripheral blood mononuclear cells as a model to study the response of energy homeostasis-related genes to acute changes in feeding conditions. OMICS. 2010; 14(2):129-41.
- Heyne A, Kiesselbach C, Sahun I, et al. An animal model of compulsive food-taking behaviour. Addict Biol. 2009; 14(4):373-83.
- Vickers SP, Jackson HC, Cheetham SC. The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol. 2011; 164(4):1248-62.
- Novelli EL, Diniz YS, Galhardi CM, et al. Anthropometrical parameters and markers of obesity in rats. Lab Anim. 2007; 41(1):111-9.
- Lewis AR, Singh S, Youssef FF. Cafeteria-diet induced obesity results in impaired cognitive functioning in a rodent model. Heliyon. 2019; 5(3):e01412.
- Sampey BP, Vanhoose AM, Winfield HM, et al. Cafeteria diet is a robust model of human metabolic syndrome with liver and adipose inflammation: comparison to high-fat diet. Obesity (Silver Spring). 2011;19(6):1109-17.
- Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5):323-9.
- Leigh SJ, Kendig MD, Morris MJ. Palatable Western-style Cafeteria Diet as a Reliable Method for Modeling Diet-induced Obesity in Rodents. J Vis Exp. 2019 (153).
- Jensterle M, Salamun V, Kocjan T, et al. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015; 8:32.
- Kim YW, Kim JY, Park YH, et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes. 2006; 55(3):716-24.
- Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 1996; 19(9):920-6.
- Jelsing J, Vrang N, Hansen G, et al. Liraglutide: short-lived effect on gastric emptying long lasting effects on body weight. Diabetes Obes Metab. 2012; 14(6):531-8.
- Yamazaki S, Satoh H, Watanabe T. Liraglutide enhances insulin sensitivity by activating AMP-activated protein kinase in male Wistar rats. Endocrinology. 2014; 155(9):3288-301.
- D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagonlike peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest. 1994; 93(5):2263-6.
- D’Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulinindependent processes. A physiological role of glucagon-like peptide I. Diabetes. 1995; 44(12):1433-7.
- Abbasi F, McLaughlin T, Lamendola C, et al. Fasting remnant lipoprotein cholesterol and triglyceride concentrations are elevated in nondiabetic, insulin-resistant, female volunteers. J Clin Endocrinol Metab. 1999; 84(11):3903-6.
- Alalwani AD, Hummdi LA, Qahl SH. Effect of nano extracts of olea europaea leaves, ficus carica and liraglutide in lipidemic liver of type 2 diabetic rat model. Saudi J Biol Sci. 2022; 29(7):103333.
- Taher J, Baker CL, Cuizon C, et al. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Mol Metab. 2014; 3(9):823-33.